PMID- 16356539
OWN - NLM
STAT- MEDLINE
DCOM- 20070118
LR  - 20151119
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 118
IP  - 5
DP  - 2006
TI  - Circulating CD40 ligand is elevated only in patients with more advanced 
      symptomatic peripheral arterial diseases.
PG  - 619-26
AB  - INTRODUCTION: CD40 and its ligand participate in atherosclerosis formation, 
      progression and destabilization. Increased soluble CD40 ligand (sCD40L) was 
      observed in hypercholesterolemia, unstable angina and conditions with platelet 
      activation. To date, there is no report on the association of sCD40L with 
      angiographic peripheral artery disease (PAD) disease severity. MATERIALS AND 
      METHODS: From March 1999 to April 2004, consecutive patients having 
      angiographically documented PAD and given consents for pre-procedural serum 
      sample use were recruited into this study. The key PAD lesions should be > or = 
      70% diameter stenotic at the lower limbs and patients were dichotomized into two 
      groups depending on total PAD lengths. Peer angiographic control subjects were 
      those free of coronary disease, PAD and major medical diseases. The serum samples 
      were thawed and analyzed for sCD40L, monocyte chemotactic protein 1 (MCP-1) and 
      hs-CRP in a single batch. RESULTS: A total of 63 well-defined lower-limb PAD 
      patients and 30 control subjects were studied. Patients with PAD lengths >5 cm 
      (N=38) presented higher sCD40L than those with lesions < or = 5 cm (N=25) 
      (5430+/-459 vs. 3889+/-507 pg/ml, p=0.037) and control subjects (5430+/-459 vs. 
      3973+/-551 pg/ml, p=0.037). However, there was no significant difference in 
      circulating MCP-1 (375+/-49 vs. 310+/-49 pg/ml and 297+/-24 pg/ml, respectively, 
      p=0.371) or hs-CRP (0.64+/-0.16 vs. 0.51+/-0.15 mg/ml and 0.46+/-0.15 mg/dl, 
      respectively, p=0.682) across three groups. PAD patients with associated coronary 
      lesions did not differ in circulating CD40L, MCP-1 or hs-CRP from without and 
      control subjects. CONCLUSIONS: Soluble CD40L was significantly elevated in 
      patients with more advanced symptomatic PAD and might be an indicator for disease 
      extent stratification. The distribution of sCD40L in PAD was not affected by 
      coronary involvement or not.
FAU - Lee, Wen-Jane
AU  - Lee WJ
AD  - Department of Education and Research, Taichung Veterans General Hospital, 
      Taichung, Taiwan.
FAU - Sheu, Wayne Huey-Herng
AU  - Sheu WH
FAU - Chen, Ying-Tsung
AU  - Chen YT
FAU - Liu, Tsun-Jui
AU  - Liu TJ
FAU - Liang, Kae-Woei
AU  - Liang KW
FAU - Ting, Chih-Tai
AU  - Ting CT
FAU - Lee, Wen-Lieng
AU  - Lee WL
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051213
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Biomarkers)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - Aged
MH  - Atherosclerosis/*blood/*diagnosis
MH  - Biomarkers/blood
MH  - CD40 Ligand/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Peripheral Vascular Diseases/*blood/*diagnosis
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - *Severity of Illness Index
EDAT- 2005/12/17 09:00
MHDA- 2007/01/19 09:00
CRDT- 2005/12/17 09:00
PHST- 2005/06/10 00:00 [received]
PHST- 2005/10/26 00:00 [revised]
PHST- 2005/10/27 00:00 [accepted]
PHST- 2005/12/17 09:00 [pubmed]
PHST- 2007/01/19 09:00 [medline]
PHST- 2005/12/17 09:00 [entrez]
AID - S0049-3848(05)00433-0 [pii]
AID - 10.1016/j.thromres.2005.10.012 [doi]
PST - ppublish
SO  - Thromb Res. 2006;118(5):619-26. doi: 10.1016/j.thromres.2005.10.012. Epub 2005 
      Dec 13.